Unlock the most comprehensive view of cancer
with our revolutionary precision oncology tests.
Unlock the most comprehensive view of cancer with our revolutionary precision oncology tests.
Our liquid and tissue tests answer critical questions across
the cancer care continuum—providing end-to-end insights
with the convenience of a single testing partner.
View test details
MAF, mutant allele fraction; MRD, minimal or molecular residual disease; MSI, microsatellite instability; TMB, tumor mutation burden.
*When compared to other tissue-free testing companies. Comparisons are based on publicly available information as of October 2025.
†Median turnaround time from sample receipt to first results.
‡Guardant Reveal is covered by Medicare to guide adjuvant therapy decision-making following surgery and for longitudinal recurrence surveillance every 3 to 6 months in colorectal cancer.
§Statement applies to Guardant360 Liquid LDT as reported in a professional service report, which is part of Guardant360 Liquid CDx. The professional service report is not reviewed nor approved by the FDA. #1 liquid biopsy statement is based on stated brand utilization from a market research survey.
¶Offered as professional services only.
#Reporting thresholds for SNVs.
||Median turnaround time from sample receipt to first results.
**Compared to other leading comprehensive tissue tests. The "most advanced" referring to the first and only commercially available tissue test to deliver multiomic insights from a single input.
††For DNA only when sample requirements are met, as of April 2026.
‡‡2mm2 for Guardant360 Tissue (for NGS testing only) vs 25mm2 industry standard.
§§Guardant360® Tissue can be ordered as a standalone or with Guardant360® Liquid CDx. Liquid and tissue testing may be initiated at the same time, but sample processing does not occur concurrently. Once the Guardant360® Liquid CDx results have been delivered, confirmation of medical necessity is required to proceed with Guardant360® Tissue. Patients who have a negative Guardant360® Liquid CDx test result for an indicated companion diagnostic marker should be reflexed to tissue biopsy testing using an FDA-approved tumor tissue test, if feasible.
¶¶Non-unique lives covered across Guardant360 Liquid CDx and Guardant360 Tissue, including overlap across tests and payers.
Important note: Guardant Reveal® and Guardant360® Tissue were developed as Laboratory Developed Tests (LDTs), and their performance characteristics determined by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA.
InfinityAI is not a standalone customer product. "Powered by InfinityAI" refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
References: 1. Guardant Reveal Assay Specifications. 2025. Guardant Health, Inc. Redwood City, CA. 2. Guardant Health Data on file. Late-stage Chart Audit. April 2026. 3. Clemens K, Bucheit L, Forbes S, Alshurafa H, Das A, Eltoukhy H. Exploring clinical actionability of expanded liquid biopsy in advanced breast and colorectal cancers. Cancer Res. 2026;86(7 suppl):6512. doi:10.1158/1538-7445.AM2026-6512 4. Tung L, Valouev A, Odegaard J, et al. Fusion epigenotyping using cell-free DNA methylation improves detection of actionable ALK fusions in non-small cell lung cancer. Abstract presented at: American Association for Cancer Research Annual Meeting; April 20, 2026; San Diego, CA. Abstract 1409. 5. Guardant Health Data on File. REC-004501 April 2026. Guardant Health, Inc. Redwood City, CA.